Best Practice & Research Clinical Rheumatology
Volume 24, Issue 1 , Pages 51-70 , February 2010

Targeting subchondral bone for treating osteoarthritis: what is the evidence?

  • Steeve Kwan Tat, PhD (Post-doctoral student, University of Montreal)
    • ,
  • Daniel Lajeunesse, PhD (Professor of Medicine, Director of Biomedical Sciences, University of Montreal)
    • ,
  • Jean-Pierre Pelletier, MD (Professor of Medicine, University of Montreal; Head, Arthritis Centre, University of Montreal; Director, Osteoarthritis Research Institute)
    • ,
  • Johanne Martel-Pelletier, PhD (Professor of Medicine, University of Montreal; Director, Osteoarthritis Research Institute)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 514 890 8000x26658; fax: +1 514 412 7582.

References 

  1. Ng KW, Romas E, Donnan L, Findlay DM. Bone biology. Baillieres Clin Endocrinol Metab. 1997;11:1–22
  2. Hill PA. Bone remodelling. Br J Orthod. 1998;25:101–107
  3. Troen BR. Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol. 2003;38:605–614
  4. Martel-Pelletier J, Lajeunesse D, Pelletier JP. Etiopathogenesis of osteoarthritis. In:  Koopman WJ,  Moreland LW editor. Arthritis & allied conditions. A textbook of rheumatology. 15th ed.. Baltimore: Lippincott, Williams & Wilkins; 2005;p. 2199–2226
  5. Carlson CS, Loeser RF, Jayo MJ, et al. Osteoarthritis in cynomolgus macaques: a primate model of naturally occurring disease. J Orthop Res. 1994;12:331–339
  6. Brandt KD, Myers SL, Burr D, Albrecht M. Osteoarthritic changes in canine articular cartilage, subchondral bone, and synovium fifty-four months after transection of the anterior cruciate ligament. Arthritis Rheum. 1991;34:1560–1570
  7. Hayami T, Pickarski M, Wesolowski GA, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum. 2004;50:1193–1206
  8. Pelletier JP, Boileau C, Brunet J, et al. The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone. 2004;34:527–538
  9. Hayami T, Pickarski M, Zhuo Y, et al. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone. 2006;38:234–243
  10. Raynauld JP, Martel-Pelletier J, Berthiaume MJ, et al. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther. 2006;8:R21
  11. Pelletier JP, Raynauld JP, Berthiaume MJ, et al. Risk factors associated with the loss of cartilage volume on weight bearing areas in knee osteoarthritis patients assessed by quantitative MRI: a longitudinal study. Arthritis Res Ther. 2007;9:R74
  12. Raynauld J-P, Martel-Pelletier J, Berthiaume M-J, et al. Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period. Ann Rheum Dis. 2008;67:683–688
  13. Boileau C, Martel-Pelletier J, Abram F, et al. Magnetic resonance imaging can accurately assess the long-term progression of knee structural changes in experimental dog OA. Ann Rheum Dis. 2008;67:926–932
  14. Blumenkrantz G, Lindsey CT, Dunn TC, et al. A pilot, two-year longitudinal study of the interrelationship between trabecular bone and articular cartilage in the osteoarthritic knee. Osteoarthritis Cartilage. 2004;12:997–1005
  15. Beuf O, Ghosh S, Newitt DC, et al. Magnetic resonance imaging of normal and osteoarthritic trabecular bone structure in the human knee. Arthritis Rheum. 2002;46:385–393
  16. Martig S, Boisclair J, Konar M, et al. MRI characteristics and histology of bone marrow lesions in dogs with experimentally induced osteoarthritis. Vet Radiol Ultrasound. 2007;48:105–112
  17. Bettica P, Cline G, Hart DJ, et al. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum. 2002;46:3178–3184
  18. Pastoureau PC, Chomel AC, Bonnet J. Evidence of early subchondral bone changes in the meniscectomized guinea pig. A densitometric study using dual-energy X-ray absorptiometry subregional analysis. Osteoarthritis Cartilage. 1999;7:466–473
  19. Buckland-Wright JC, Macfarlane DG, Lynch JA, Clark B. Quantitative microfocal radiographic assessment of progression in osteoarthritis of the hand. Arthritis Rheum. 1990;33:57–65
  20. Buckland-Wright JC, Lynch JA, Macfarlane DG. Fractal signature analysis measures cancellous bone organisation in macroradiographs of patients with knee osteoarthritis. Ann Rheum Dis. 1996;55:749–755
  21. Sharif M, George E, Dieppe PA. Correlation between synovial fluid markers of cartilage and bone turnover and scintigraphic scan abnormalities in osteoarthritis of the knee. Arthritis Rheum. 1995;38:78–81
  22. Dieppe P, Cushnaghan J, Young P, Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis. 1993;52:557–563
  23. McCarthy C, Cushnaghan J, Dieppe P. The predictive role of scintigraphy in radiographic osteoarthritis of the hand. Osteoarthritis Cartilage. 1994;2:25–28
  24. Gevers G, Dequeker J. Collagen and non-collagenous protein content (osteocalcin, sialoprotein, proteoglycan) in the iliac crest bone and serum osteocalcin in women with and without hand osteoarthritis. Coll Relat Res. 1987;7:435–442
  25. Dequeker J, Mohan R, Finkelman RD, et al. Generalized osteoarthritis associated with increased insulin-like growth factor types I and II and transforming growth factor beta in cortical bone from the iliac crest. Possible mechanism of increased bone density and protection against osteoporosis. Arthritis Rheum. 1993;36:1702–1708
  26. Ferguson VL, Bushby AJ, Boyde A. Nanomechanical properties and mineral concentration in articular calcified cartilage and subchondral bone. J Anat. 2003;203:191–202
  27. Crane GJ, Fazzalari NL, Parkinson IH, Vernon-Roberts B. Age-related changes in femoral trabecular bone in arthrosis. Acta Orthop Scand. 1990;61:421–426
  28. Fazzalari NL, Parkinson IH. Femoral trabecular bone of osteoarthritic and normal subjects in an age and sex matched group. Osteoarthritis Cartilage. 1998;6:377–382
  29. Grynpas MD, Alpert B, Katz I, et al. Subchondral bone in osteoarthritis. Calcif Tissue Int. 1991;49:20–26
  30. Li B, Aspden RM. Composition and mechanical properties of cancellous bone from the femoral head of patients with osteoporosis or osteoarthritis. J Bone Miner Res. 1997;12:641–651
  31. Mansell JP, Tarlton JF, Bailey AJ. Biochemical evidence for altered subchondral bone collagen metabolism in osteoarthritis of the hip. Br J Rheumatol. 1997;36:16–19
  32. Mansell JP, Bailey AJ. Abnormal cancellous bone collagen metabolism in osteoarthritis. J Clin Invest. 1998;101:1596–1603
  33. Bailey AJ, Sims TJ, Knott L. Phenotypic expression of osteoblast collagen in osteoarthritic bone: production of type I homotrimer. Int J Biochem Cell Biol. 2002;34:176–182
  34. Gevers G, Dequeker J, Geusens P, et al. Physical and histomorphological characteristics of iliac crest bone differ according to the grade of osteoarthritis at the hand. Bone. 1989;10:173–177
  35. Zysset PK, Sonny M, Hayes WC. Morphology-mechanical property relations in trabecular bone of the osteoarthritic proximal tibia. J Arthroplasty. 1994;9:203–216
  36. Couchourel D, Aubry I, Delalandre A, et al. Altered mineralization of human osteoarthritic osteoblasts is due to abnormal collagen type 1 production. Arthritis Rheum. 2009;60:1438–1450
  37. Hilal G, Martel-Pelletier J, Pelletier JP, et al. Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: possible role in subchondral bone sclerosis. Arthritis Rheum. 1998;41:891–899
  38. Hilal G, Martel-Pelletier J, Pelletier JP, et al. Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts. Arthritis Rheum. 1999;42:2112–2122
  39. Aspden RM, Scheven BA, Hutchison JD. Osteoarthritis as a systemic disorder including stromal cell differentiation and lipid metabolism. Lancet. 2001;357:1118–1120
  40. Plumb MS, Aspden RM. High levels of fat and (n−6) fatty acids in cancellous bone in osteoarthritis. Lipids Health Dis. 2004;3:12
  41. Murphy JM, Dixon K, Beck S, et al. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum. 2002;46:704–713
  42. Thomas T, Gori F, Khosla S, et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 1999;140:1630–1638
  43. Gordeladze JO, Drevon CA, Syversen U, Reseland JE. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem. 2002;85:825–836
  44. Bennett CN, Ross SE, Longo KA, et al. Regulation of Wnt signaling during a dipogenesis. J Biol Chem. 2002;277:30998–31004
  45. Fox KE, Colton LA, Erickson PF, et al. Regulation of cyclin D1 and Wnt10b gene expression by cAMP-responsive element-binding protein during early adipogenesis involves differential promoter methylation. J Biol Chem. 2008;283:35096–35105
  46. Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Fed Am Soc Exp Bio J. 2005;19:1842–1844
  47. van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 2005;16:319–327
  48. Couchourel D, Delalandre A, Lajeunesse D. Increased expression of Wnt inhibitory factors in subchondral osteoblasts from osteoarthritic patients could play a role in their abnormal phenotype and mineralization. Ann Rheum Dis. 2008;67(Suppl. II):98;[abstract]
  49. Li X, Liu P, Liu W, et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet. 2005;37:945–952
  50. Robinson JA, Chatterjee-Kishore M, Yaworsky PJ, et al. Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem. 2006;281:31720–31728
  51. Liu J, Zou L, Wang J, et al. Hydrostatic pressure promotes Wnt10b and Wnt4 expression dependent and independent on ERK signaling in early-osteoinduced MSCs. Biochem Biophys Res Commun. 2009;379:505–509
  52. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346:1513–1521
  53. Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002;70:11–19
  54. Babij P, Zhao W, Small C, et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res. 2003;18:960–974
  55. Hartmann C. A Wnt canon orchestrating osteoblastogenesis. Trends Cell Biol. 2006;16:151–158
  56. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107:513–523
  57. Kato M, Patel MS, Levasseur R, et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol. 2002;157:303–314
  58. Smith AJ, Gidley J, Sandy JR, et al. Haplotypes of the low-density lipoprotein receptor-related protein 5 (LRP5) gene: are they a risk factor in osteoarthritis?. Osteoarthritis Cartilage. 2005;13:608–613
  59. Loughlin J, Dowling B, Chapman K, et al. Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. Proc Natl Acad Sci USA. 2004;101:9757–9762
  60. Chung YS, Baylink DJ, Srivastava AK, et al. Effects of secreted frizzled-related protein 3 on osteoblasts in vitro. J Bone Miner Res. 2004;19:1395–1402
  61. Li J, Sarosi I, Cattley RC, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006;39:754–766
  62. Morvan F, Boulukos K, Clement-Lacroix P, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21:934–945
  63. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13:156–163
  64. Gardner JC, van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab. 2005;90:6392–6395
  65. Winkler DG, Sutherland MS, Ojala E, et al. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem. 2005;280:2498–2502
  66. Fischer L, Boland G, Tuan RS. Wnt-3A enhances bone morphogenetic protein-2-mediated chondrogenesis of murine C3H10T1/2 mesenchymal cells. J Biol Chem. 2002;277:30870–30878
  67. Bain G, Muller T, Wang X, Papkoff J. Activated beta-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem Biophys Res Commun. 2003;301:84–91
  68. Zamurovic N, Cappellen D, Rohner D, Susa M. Coordinated activation of notch, Wnt, and transforming growth factor-beta signaling pathways in bone morphogenic protein 2-induced osteogenesis. Notch target gene Hey1 inhibits mineralization and Runx2 transcriptional activity. J Biol Chem. 2004;279:37704–37715
  69. Massicotte F, Fernandes JC, Martel-Pelletier J, et al. Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts. Bone. 2006;38:333–341
  70. Rydziel S, Delany AM, Canalis E. Insulin-like growth factor I inhibits the transcription of collagenase 3 in osteoblast cultures. J Cell Biochem. 1997;67:176–183
  71. van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB. Transforming growth factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. Lab Invest. 1994;71:279–290
  72. Scharstuhl A, Glansbeek HL, van Beuningen HM, et al. Inhibition of endogenous TGF-beta during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. J Immunol. 2002;169:507–514
  73. Dumond H, Presle N, Terlain B, et al. Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum. 2003;48:3118–3129
  74. Darnay BG, Haridas V, Ni J, et al. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappaB and c-Jun N-terminal kinase. J Biol Chem. 1998;273:20551–20555
  75. Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum. 2000;43:2143–2151
  76. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142:5050–5055
  77. Armstrong AP, Tometsko ME, Glaccum M, et al. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem. 2002;277:44347–44356
  78. Kwan Tat S, Padrines M, Theoleyre S, et al. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004;15:49–60
  79. Kwan Tat S, Pelletier JP, Lajeunesse D, et al. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol. 2008;26:295–304
  80. Zhao C, Irie N, Takada Y, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006;4:111–121
  81. Kwan Tat S, Pelletier JP, Amiable N, et al. Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts: a new therapeutic approach. Arthritis Rheum. 2008;58:3820–3830
  82. Hilal G, Massicotte F, Martel-Pelletier J, et al. Endogenous prostaglandin E2 and insulin-like growth factor 1 can modulate the levels of parathyroid hormone receptor in human osteoarthritic osteoblasts. J Bone Miner Res. 2001;16:713–721
  83. Dietrich JW, Canalis EM, Maina DM, Raisz LG. Hormonal control of bone collagen synthesis in vitro: effects of parathyroid hormone and calcitonin. Endocrinology. 1976;98:943–949
  84. Beresford JN, Gallagher JA, Poser JW, Russell RG. Production of osteocalcin by human bone cells in vitro. Effects of 1,25(OH)2D3, 24,25(OH)2D3, parathyroid hormone, and glucocorticoids. Metab Bone Dis Relat Res. 1984;5:229–234
  85. Coats AM, Zioupos P, Aspden RM. Material properties of subchondral bone from patients with osteoporosis or osteoarthritis by microindentation testing and electron probe microanalysis. Calcif Tissue Int. 2003;73:66–71
  86. Burr DB. Increased biological activity of subchondral mineralized tissues underlies the progressive deterioration of articular cartilage in osteoarthritis. J Rheumatol. 2005;32:1156–1158[discussion 1158–1159]
  87. Mital MA, Millington PF. Osseous pathway of nutrition to articular cartilage of the human femoral head. Lancet. 1970;1:842
  88. Mori S, Harruff R, Burr DB. Microcracks in articular calcified cartilage of human femoral heads. Arch Pathol Lab Med. 1993;117:196–198
  89. Sokoloff L. Microcracks in the calcified layer of articular cartilage. Arch Pathol Lab Med. 1993;117:191–195
  90. Villanueva AR, Longo JA, Weiner G. Staining and histomorphometry of microcracks in the human femoral head. Biotech Histochem. 1994;69:81–88
  91. Burr DB, Radin EL. Microfractures and microcracks in subchondral bone: are they relevant to osteoarthrosis?. Rheum Dis Clin North Am. 2003;29:675–685
  92. Laurent UB, Fraser JR, Engstrom-Laurent A, et al. Catabolism of hyaluronan in the knee joint of the rabbit. Matrix. 1992;12:130–136
  93. Malinin T, Ouellette EA. Articular cartilage nutrition is mediated by subchondral bone: a long-term autograft study in baboons. Osteoarthritis Cartilage. 2000;8:483–491
  94. Huebner JL, Hanes MA, Beekman B, et al. A comparative analysis of bone and cartilage metabolism in two strains of guinea-pig with varying degrees of naturally occurring osteoarthritis. Osteoarthritis Cartilage. 2002;10:758–767
  95. Radin EL, Rose RM. Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop. 1986;213:34–40
  96. Carlson CS, Loeser RF, Purser CB, et al. Osteoarthritis in cynomolgus macaques. III: effects of age, gender, and subchondral bone thickness on the severity of disease. J Bone Miner Res. 1996;11:1209–1217
  97. Brandt KD. Insights into the natural history of osteoarthritis provided by the cruciate-deficient dog. An animal model of osteoarthritis. Ann NY Acad Sci. 1994;732:199–205[Review]
  98. Burr DB. The importance of subchondral bone in osteoarthrosis. Curr Opin Rheumatol. 1998;10:256–562
  99. Burr DB, Schaffler MB. The involvement of subchondral mineralized tissues in osteoarthrosis: quantitative microscopic evidence. Microsc Res Tech. 1997;37:343–357
  100. Imhof H, Breitenseher M, Kainberger F, et al. Importance of subchondral bone to articular cartilage in health and disease. Top Magn Reson Imaging. 1999;10:180–192
  101. Kwan Tat S, Amiable N, Pelletier JP, et al. Modulation of OPG, RANK, and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatology (in press).
  102. Kwan Tat S, Pelletier JP, Amiable N, et al. Treatment with ephrin B2 positively impacts the abnormal metabolism of human osteoarthritic chondrocytes. Arthritis Res Ther. 2009;11:R119
  103. Pfander D, Cramer T, Weseloh G, et al. Hepatocyte growth factor in human osteoarthritic cartilage. Osteoarthritis Cartilage. 1999;7:548–559
  104. Blanquaert F, Pereira RC, Canalis E. Cortisol inhibits hepatocyte growth factor/scatter factor expression and induces c-met transcripts in osteoblasts. Am J Physiol Endocrinol Metab. 2000;278:E509–E515
  105. Guévremont M, Martel-Pelletier J, Massicotte F, et al. Human adult chondrocytes express hepatocyte growth factor (HGF) isoforms but not HGF: potential implication of osteoblasts on the presence of HGF in cartilage. J Bone Miner Res. 2003;18:1073–1081
  106. Reboul P, Pelletier JP, Tardif G, et al. Hepatocyte growth factor induction of collagenase 3 production in human osteoarthritic cartilage: involvement of the stress-activated protein kinase/c-Jun N-terminal kinase pathway and a sensitive p38 mitogen-activated protein kinase inhibitor cascade. Arthritis Rheum. 2001;44:73–84
  107. Moldovan F, Pelletier JP, Hambor J, et al. Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ: in vitro mimicking effect by transforming growth factor beta. Arthritis Rheum. 1997;40:1653–1661
  108. Berthiaume MJ, Raynauld JP, Martel-Pelletier J, et al. Meniscal tear and extrusion are strongly associated with the progression of knee osteoarthritis as assessed by quantitative magnetic resonance imaging. Ann Rheum Dis. 2005;64:556–563
  109. Bruyere O, Collette J, Kothari M, et al. Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Ann Rheum Dis. 2006;65:1050–1054
  110. Jung YO, Do JH, Kang HJ, et al. Correlation of sonographic severity with biochemical markers of synovium and cartilage in knee osteoarthritis patients. Clin Exp Rheumatol. 2006;24:253–259
  111. Sharif M, Kirwan J, Charni N, et al. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis–association with disease progression. Rheumatology (Oxford). 2007;46:938–943
  112. Conrozier T, Poole AR, Ferrand F, et al. Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis. Clin Exp Rheumatol. 2008;26:430–435
  113. Chaganti RK, Kelman A, Lui L, et al. Change in serum measurements of cartilage oligomeric matrix protein and association with the development and worsening of radiographic hip osteoarthritis. Osteoarthritis Cartilage. 2008;16:566–571
  114. Hunter DJ, Lavalley M, Li J, et al. Biochemical markers of bone turnover and their association with bone marrow lesions. Arthritis Res Ther. 2008;10:R102
  115. Kong SY, Stabler TV, Criscione LG, et al. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum. 2006;54:2496–2504
  116. Pothacharoen P, Teekachunhatean S, Louthrenoo W, et al. Raised chondroitin sulfate epitopes and hyaluronan in serum from rheumatoid arthritis and osteoarthritis patients. Osteoarthritis Cartilage. 2006;14:299–301
  117. Jordan KM, Syddall HE, Garnero P, et al. Urinary CTX-II and glucosyl-galactosyl-pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men. Ann Rheum Dis. 2006;65:871–877
  118. Davis CR, Karl J, Granell R, et al. Can biochemical markers serve as surrogates for imaging in knee osteoarthritis?. Arthritis Rheum. 2007;56:4038–4047
  119. Meulenbelt I, Kloppenburg M, Kroon HM, et al. Clusters of biochemical markers are associated with radiographic subtypes of osteoarthritis (OA) in subject with familial OA at multiple sites. The GARP study. Osteoarthritis Cartilage. 2007;15:379–385
  120. Pilichou A, Papassotiriou I, Michalakakou K, et al. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. Clin Biochem. 2008;41:746–749
  121. Ling SM, Patel DD, Garnero P, et al. Serum protein signatures detect early radiographic osteoarthritis. Osteoarthritis Cartilage. 2009;17:43–48
  122. Cibere J, Zhang H, Garnero P, et al. Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum. 2009;60:1372–1380
  123. Kadri A, Ea HK, Bazille C, et al. Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. Arthritis Rheum. 2008;58:2379–2386
  124. Shimizu S, Asou Y, Itoh S, et al. Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. Arthritis Rheum. 2007;56:3358–3365
  125. Nakashima T, Wada T, Penninger JM. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol. 2003;15:280–287
  126. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19:1059–1066
  127. Ding M, Danielsen CC, Hvid I. The effects of bone remodeling inhibition by alendronate on three-dimensional microarchitecture of subchondral bone tissues in guinea pig primary osteoarthrosis. Calcif Tissue Int. 2008;82:77–86
  128. Meyer J, Farmer R, Prenger MC. Risedronate but not alendronate slows disease progression in the guinea pig model of primary osteoarthritis. J Bone Miner Res. 2001;5305:SA472;[abstract]
  129. Meyer JM, Dansereau SM, Farmer RW, et al. Bisphosphonates structurally similar to risedronate (actonel) slow disease progression in the guinea pig model of primary osteoarthritis. Arthritis Rheum. 2001;44(5307):1527;[abstract]
  130. Myers SL, Brandt KD, Burr DB, et al. Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis. J Rheumatol. 1999;26:2645–2653
  131. Spector TD, Conaghan PG, Buckland-Wright JC, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res Ther. 2005;7:R625–R633
  132. Bingham CO, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 2006;54:3494–3507
  133. Hott M, Deloffre P, Tsouderos Y, Marie PJ. S12911-2 reduces bone loss induced by short-term immobilization in rats. Bone. 2003;33:115–123
  134. Marie PJ, Hott M, Modrowski D, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res. 1993;8:607–615
  135. Ammann P, Shen V, Robin B, et al. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res. 2004;19:2012–2020
  136. Buehler J, Chappuis P, Saffar JL, et al. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone. 2001;29:176–179
  137. Delannoy P, Bazot D, Marie PJ. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism. 2002;51:906–911
  138. Barbara A, Delannoy P, Denis BG, Marie PJ. Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells. Metabolism. 2004;53:532–537
  139. Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol. 2002;450:11–17
  140. Canalis E, Hott M, Deloffre P, et al. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone. 1996;18:517–523
  141. Fromigue O, Hay E, Barbara A, et al. Calcium sensing receptor-dependent and -independent activation of osteoblast replication and survival by strontium ranelate. J Cell Mol Med. 2009;[epub ahead of print]
  142. Takahashi N, Sasaki T, Tsouderos Y, Suda TS. 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res. 2003;18:1082–1087
  143. Papaioannou NA, Triantafillopoulos IK, Khaldi L, et al. Effect of calcitonin in early and late stages of experimentally induced osteoarthritis. A histomorphometric study. Osteoarthritis Cartilage. 2007;15:386–395
  144. Manicourt DH, Altman RD, Williams JM, et al. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum. 1999;42:1159–1167
  145. El Hajjaji H, Williams JM, Devogelaer JP, et al. Treatment with calcitonin prevents the net loss of collagen, hyaluronan and proteoglycan aggregates from cartilage in the early stages of canine experimental osteoarthritis. Osteoarthritis Cartilage. 2004;12:904–911
  146. Manicourt DH, Azria M, Mindeholm L, et al. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum. 2006;54:3205–3211
  147. Konttinen YT, Mandelin J, Li TF, et al. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum. 2002;46:953–960
  148. Kafienah W, Bromme D, Buttle DJ, et al. Human cathepsin K cleaves native type I and II collagens at the N- terminal end of the triple helix. Biochem J. 1998;331(Pt 3):727–732
  149. Sniekers YH, Weinans H, Bierma-Zeinstra SM, et al. Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment - a systematic approach. Osteoarthritis Cartilage. 2008;16:533–541
  150. Karsdal MA, Byrjalsen I, Leeming DJ, Christiansen C. Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation. BMC Musculoskelet Disord. 2008;9:153
  151. Christgau S, Cloos PA. Sex hormones in the regulation of bone and cartilage metabolism: an old paradigm and a new challenge. Minerva Ginecol. 2005;57:611–617
  152. Tetlow LC, Woolley DE. Expression of vitamin D receptors and matrix metalloproteinases in osteoarthritic cartilage and human articular chondrocytes in vitro. Osteoarthritis Cartilage. 2001;9:423–431
  153. McAlindon TE, Felson DT, Zhang Y, et al. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med. 1996;125:353–359
  154. Lane NE, Gore LR, Cummings SR, et al. Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: a longitudinal study. Study of Osteoporotic Fractures Research Group. Arthritis Rheum. 1999;42:854–860
  155. Felson DT, Niu J, Clancy M, et al. Low levels of vitamin D and worsening of knee osteoarthritis: results of two longitudinal studies. Arthritis Rheum. 2007;56:129–136
  156. Hunter DJ, Hart D, Snieder H, et al. Evidence of altered bone turnover, vitamin D and calcium regulation with knee osteoarthritis in female twins. Rheumatology (Oxford). 2003;42:1311–1316
  157. Ding C, Cicuttini F, Parameswaran V, et al. Serum levels of vitamin D, sunlight exposure, and knee cartilage loss in older adults: the Tasmanian older adult cohort study. Arthritis Rheum. 2009;60:1381–1389
  158. Dougados M, Nguyen M, Berdah L, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum. 2001;44:2539–2547
  159. Pelletier JP, Lajeunesse D, Reboul P, et al. Diacerein reduces the excess synthesis of bone remodeling factors by human osteoblast cells from osteoarthritic subchondral bone. J Rheumatol. 2001;28:814–824
  160. Boileau C, Tat SK, Pelletier JP, et al. Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. Arthritis Res Ther. 2008;10:R71
  161. Boileau C, Martel-Pelletier J, Caron C, et al. Protective effects of total fraction of avocado/soybean unsaponifiables (ASU) on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and MMP-13. Arthritis Res Ther. 2009;11:R41
  162. Kawcak CE, Frisbie DD, McIlwraith CW, et al. Evaluation of avocado and soybean unsaponifiable extracts for treatment of horses with experimentally induced osteoarthritis. Am J Vet Res. 2007;68:598–604
  163. Cake MA, Read RA, Guillou B, Ghosh P. Modification of articular cartilage and subchondral bone pathology in an ovine meniscectomy model of osteoarthritis by avocado and soya unsaponifiables (ASU). Osteoarthritis Cartilage. 2000;8:404–411
  164. Maheu E, Mazieres B, Valat JP, et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum. 1998;41:81–91
  165. Lequesne M, Maheu E, Cadet C, Dreiser RL. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum. 2002;47:50–58
  166. Wang SX, Laverty S, Dumitriu M, et al. The effects of glucosamine hydrochloride on subchondral bone changes in an animal model of osteoarthritis. Arthritis Rheum. 2007;56:1537–1548
  167. Tat SK, Pelletier JP, Vergés J, et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts. Arthritis Res Ther. 2007;9:R117
  168. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. J Am Med Assoc. 2000;283:1469–1475
  169. Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med. 2003;163:1514–1522

PII: S1521-6942(09)00087-4

doi: 10.1016/j.berh.2009.08.004

Best Practice & Research Clinical Rheumatology
Volume 24, Issue 1 , Pages 51-70 , February 2010

Article Tools

* Image Usage & Resolution